Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN121121,70,75
Msft78,6378,640,92
IBM161,34161,370,31
DCX68,3368,36-0,84
PFE36,136,11-0,39
20.10.2017 17:33:58
Indexy online
AD Index online
select
AD Index online
 

  • 19.10.2017 23:20:01
Spotlight (US Other OTC (Pink Sheets))
Závěr k 19.10.2017 Změna (%) Změna (USD) Objem obchodů (ks)
0,1001 -17,27 -0,02 3 650
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.10.2017
Popis společnosti
Obecné informace
Název společnostiSpotlight Innovation Inc
TickerSTLT
Kmenové akcie:Ordinary Shares
RICSTLT.PK
ISINUS8492071050
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2012 0
Akcie v oběhu k 16.8.2017 32 935 343
MěnaUSD
Kontaktní informace
Ulice11147 Aurora Ave Bldg 3
MěstoURBANDALE
PSČ50322-7904
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon15 152 749 087

Business Summary: Spotlight Innovation Inc., formerly American Exploration Corporation, is a bioscience company. The Company is focused on acquiring the rights, through acquisition, license or otherwise, to various technologies. The Company is engaged in identifying and targeting technology candidates, including cancer drugs and treatment therapies for various disease states; drug and related treatment therapies for various infectious diseases, and other technology candidates. The Company focuses on diseases that are rare, which are known as orphan diseases, or new or common but underserved, such as feline chronic kidney disease. As of December 31, 2015, the Company had three subsidiaries: Celtic Biotech Iowa, Inc., CDT Veterinary Therapeutics, Inc. and Memcine Pharmaceuticals, Inc. Through its subsidiary, Celtic Biotech Iowa, Inc., it develops a range of drug candidates, such as Crotoxin, Cardiotoxin, VRCTC310 and Crotamine. Through its subsidiary, Memcine Pharmaceuticals, Inc., it offers Immunoplex.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Spotlight Innovation Inc revenues was not reported. Net loss before extraordinary items increased 41% to $3.6M. Higher net loss reflects Interest expense increase from $326K to $899K (expense), Research and development expense increase from $113K to $567K (expense), General and administrative expenses increase of 11% to $2.4M (expense).
Odvětvová klasifikace
TRBC2009Oil / Gas Exploration / Production
TRBC2012Medical Equipment, Supplies & Distribution - NEC
RBSS2004Oil & Gas Exploration & Production
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICOil And Gas Field Services, Nec
SICCommercial Physical Research



  • Poslední aktualizace: 20.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Interim Chief Executive Officer, Chief Operating OfficerJohn Krohn-23.5.201728.12.2016
Chief Financial OfficerJohn Pim626.11.20156.11.2015